News for 'Aurobindo Pharma Ltd'

Leadership change not related to Jagan: Aurobindo Pharma

Leadership change not related to Jagan: Aurobindo Pharma

Rediff.com1 Jun 2012

The company on Wednesday said P V Ramprasad Reddy would resign as executive chairman, while Nithyananda would also step down from his post.

Aurobindo Pharma Q3 net at Rs 21.15 cr

Aurobindo Pharma Q3 net at Rs 21.15 cr

Rediff.com31 Jan 2003

Aurobindo Pharma Ltd has posted a net profit of Rs 211.50 million for the quarter ended December 31, 2002 as compared to Rs 201.00 million in the quarter ended December 31, 2001.

Aurobindo Pharma embroiled in patent cases in the US

Aurobindo Pharma embroiled in patent cases in the US

Rediff.com28 Apr 2014

According to the petition copies, Hospira has alleged that Aurobindo's Abbreviated New Drug Application (ANDA) to make generic version of dexmedetomidine hydrochloride injection would infringe its patented drug Precedex.

Aurobindo buys UK's Milpharm

Aurobindo buys UK's Milpharm

Rediff.com10 Feb 2006

In its first acquisition in Europe, Aurobindo Pharma Ltd today said it has acquired UK-based Milpharm Ltd, in an all cash deal, from Whyte Group and Iracot Ltd.

US drug regulator to inspect Aurobindo facilities

US drug regulator to inspect Aurobindo facilities

Rediff.com16 Aug 2012

Import alert on unit-6 facility might be lifted by FDA by Sept.

Aurobindo drugs in WHO's list

Aurobindo drugs in WHO's list

Rediff.com19 Dec 2005

Aurobindo Pharma Ltd on Monday said its Anti-retro viral products have been included in World Health Organisation's pre-qualification list.

Aurobindo's drug in WHO list

Aurobindo's drug in WHO list

Rediff.com12 Dec 2005

Aurobindo Pharma Ltd on Monday said its product Nevirapine tablets 200 mg, has been included by World Health Organisation in its pre-qualification list.

USFDA nod for Aurobindo's AIDS drug

USFDA nod for Aurobindo's AIDS drug

Rediff.com11 Jul 2005

The United States Food and Drug Administration has given tentative approval to the fixed-dose combination drug products lamivudine and zidovudine tablets -- manufactured by Aurobindo Pharma Ltd.

Aurobindo gets FDA nod for drug

Aurobindo gets FDA nod for drug

Rediff.com27 Sep 2005

Aurobindo Pharma Ltd on Tuesday said it has received tentative approval from the US FDA for its Sertraline

Delhi Excise policy: ED arrests 2 pharma executives

Delhi Excise policy: ED arrests 2 pharma executives

Rediff.com10 Nov 2022

Benoy Babu of Pernod Ricard and Sharath Reddy of Aurobindo Pharma have been arrested under sections of the PMLA.

Pfizer moves US court against Aurobindo, Dr Reddy's over cancer drug

Pfizer moves US court against Aurobindo, Dr Reddy's over cancer drug

Rediff.com17 Nov 2020

Pfizer Inc and its group companies filed a petition in a US court against Aurobindo Pharma Ltd and Dr Reddy's Laboratories alleging that the Indian drug-makers were planning separately to come out with generic versions of its blockbuster multi-billion dollar drug Ibrance (palbociclib) before expiration of its patent.

A bitter pill for Aurobindo's sterile drug unit

A bitter pill for Aurobindo's sterile drug unit

Rediff.com25 Nov 2019

USFDA issues Form 483 with as many as 14 observations that could impact ongoing operations at Aurobindo's Pashamailaram facility in Hyderabad.

Factors that will drive the markets this week

Factors that will drive the markets this week

Rediff.com25 May 2025

Movement in the equity market this week will be guided by a host of macroeconomic data announcements, global trends and trading activity of foreign investors, analysts said. Stocks markets concluded the last week on a subdued note, as investors grappled with global uncertainties.

Rosier year-end seen for Indian pharma, thanks to faster US approvals

Rosier year-end seen for Indian pharma, thanks to faster US approvals

Rediff.com12 Oct 2015

Rosier year-end seen for Indian pharma thanks to faster US approvals.

'Pradhan Mantri Hafta Vasuli Yojana': Cong on electoral bonds

'Pradhan Mantri Hafta Vasuli Yojana': Cong on electoral bonds

Rediff.com18 Mar 2024

"Remember, the IT Department and the ED implement the Pradhan Mantri Hafta Vasuli Yojana. The State Bank of India implements the #ElectoralBondScam. And at the end of the day, all of these institutions report to the same person: the Finance Minister," Ramesh alleged.

What shares should you invest in if you had Rs 5 lakh?

What shares should you invest in if you had Rs 5 lakh?

Rediff.com23 Jan 2020

Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.

Excise policy: AAP's Goa poll kickbacks detected in I-T, CBI probes, says ED

Excise policy: AAP's Goa poll kickbacks detected in I-T, CBI probes, says ED

Rediff.com31 Mar 2024

Statements of five 'Angadiya' firm operators have also been recorded by the ED to establish the "money trail" of this alleged Rs 45 crore bribe amount.

Is my portfolio good?'

Is my portfolio good?'

Rediff.com31 Jan 2022

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

ASK AJIT: 'How can I make money?'

ASK AJIT: 'How can I make money?'

Rediff.com24 Feb 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.

ASK AJIT: How to get 20% return on shares?

ASK AJIT: How to get 20% return on shares?

Rediff.com17 Dec 2021

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

Pharma in 2014: Deals worth billions and fines worth millions

Pharma in 2014: Deals worth billions and fines worth millions

Rediff.com26 Dec 2014

In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.

Ask Ajit: 'Bought shares at peak; please advice'

Ask Ajit: 'Bought shares at peak; please advice'

Rediff.com30 Mar 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Markets ends flat; Sensex posts best monthly gain in over 4 years

Markets ends flat; Sensex posts best monthly gain in over 4 years

Rediff.com31 Mar 2016

The S&P BSE Sensex ended the session at 25,342, up 3 points while the Nifty50 closed at 7,738 points.

Sensex edges up; gains 70 points at close

Sensex edges up; gains 70 points at close

Rediff.com24 Aug 2016

Covering-up of short positions ahead of Thursday's expiry of August series in the derivatives segment gave equities a slight push

Markets snap 2-day rally; post 3rd weekly gains

Markets snap 2-day rally; post 3rd weekly gains

Rediff.com8 Jun 2018

Sun Pharma was by far the biggest gainer in the Sensex pack, surging 8.13 per cent, followed by Dr Reddy's at 4.92 per cent.

New IPL teams: Goenka gets Lucknow; CVC bags Ahmedabad

New IPL teams: Goenka gets Lucknow; CVC bags Ahmedabad

Rediff.com25 Oct 2021

Kolkata-based business tycoon Sanjiv Goenka's RP-SG Group claimed the Lucknow franchise for a whopping Rs 7090 crore, while international equity investment firm CVC Capital won the bid for Ahmedabad with a Rs 5600 crore offer.

India scraps import duties on AIDS drugs to battle shortage

India scraps import duties on AIDS drugs to battle shortage

Rediff.com11 Jun 2015

Drugs under exemption make up roughly 95 per cent of the antiretrovirals used by India's AIDS patients

ASK AJIT: 'I am new to trading, need your advice'

ASK AJIT: 'I am new to trading, need your advice'

Rediff.com8 Dec 2021

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

The puzzle of India's lack of manufacturing job growth

The puzzle of India's lack of manufacturing job growth

Rediff.com21 May 2014

Top companies added employees at 3% CAGR from 2003-04 to 2013-14, while revenues grew at 18%.

Manish Sisodia arrested after 8-hr grilling, CBI says wasn't cooperating

Manish Sisodia arrested after 8-hr grilling, CBI says wasn't cooperating

Rediff.com26 Feb 2023

Sisodia was arrested after nearly eight hours of questioning on various aspects of the excise policy for 2021-22, which the probe agency says suffered from irregularities both in its formulation and implementation, allegedly intended to benefit people with links to the AAP.

ASK AJIT: Stocks To Buy, Sell, Hold

ASK AJIT: Stocks To Buy, Sell, Hold

Rediff.com24 Jan 2022

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

ASK AJIT: 'Suffering huge losses in stock market. Please help'

ASK AJIT: 'Suffering huge losses in stock market. Please help'

Rediff.com24 Dec 2021

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

First-time investor: 'I can afford only low-price stocks'

First-time investor: 'I can afford only low-price stocks'

Rediff.com12 Jan 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Markets snap 5-day winning streak; Nifty holds 8,150

Markets snap 5-day winning streak; Nifty holds 8,150

Rediff.com31 May 2016

Markets ended lower amid volatile trade with Sun Pharma leading the decline.

US Fed rate hike boosts Sensex by 309 points; Nifty ends near 7,850

US Fed rate hike boosts Sensex by 309 points; Nifty ends near 7,850

Rediff.com17 Dec 2015

Index heavyweight RIL surged 3% to end above Rs 1,000 mark while IT majors were also the top gainers.

Do you own these stocks? EXIT them NOW

Do you own these stocks? EXIT them NOW

Rediff.com22 Sep 2020

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Markets sink as Budget session begins

Markets sink as Budget session begins

Rediff.com23 Feb 2016

Mixed global cues and decline in crude oil prices further dent the sentiments.

Stocks You Must AVOID or EXIT

Stocks You Must AVOID or EXIT

Rediff.com26 Apr 2022

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Ask Ajit: Stocks to buy, sell, or hold

Ask Ajit: Stocks to buy, sell, or hold

Rediff.com26 Feb 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Just started investing in stocks? Here's some advice

Just started investing in stocks? Here's some advice

Rediff.com3 Dec 2020

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.